Has Stephanie Chiu received payments from drug or device companies?

Yes. Drug and device makers reported $10,044 in general payments to Stephanie Chiu across 393 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephanie Chiu did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephanie Chiu come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephanie Chiu

Nurse Practitioner · Walnut Creek, CANPI 1043091663

Payments from drug & device makers

$10,044in general payments, 2019–2025

Across 393 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Johnson & Johnson$951
Pfizer$735
Merck$691
Genentech USA, Inc.$414
Daiichi Sankyo Inc.$396
plus $5K from 54 others

What the payments were for

Food & beverage$9,38593%
Education$6597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	45	$1,344
Johnson & Johnson	44	$951
Pfizer	35	$735
Merck	26	$691
Genentech USA, Inc.	16	$414
Daiichi Sankyo Inc.	19	$396
GSK	14	$328
Lilly USA, LLC	9	$316
Karyopharm Therapeutics Inc.	14	$288
Astellas Pharma US Inc	5	$273
Seagen Inc.	3	$265
Spectrum Pharmaceuticals Inc.	8	$211
Incyte Corporation	5	$205
Sobi, Inc	7	$192
AVEO Pharmaceuticals, Inc.	6	$185
Array Biopharma Inc	10	$183
E.r. Squibb & Sons, L.L.C.	8	$178
Sanofi	6	$170
AbbVie	8	$161
Novartis	5	$152
Takeda Pharmaceuticals U.S.A., Inc.	7	$150
Kyowa Kirin, Inc.	5	$139
Bristol Myers Squibb	6	$137
EMD Serono, Inc.	5	$125
Coherus Oncology, Inc.	4	$115
Puma Biotechnology, Inc.	4	$112
Eisai Inc.	5	$112
Acrotech Biopharma Inc.	4	$92
Invivyd Inc	3	$84
Taiho Oncology, Inc.	3	$82
Genmab U.S., Inc.	3	$71
Sun Pharmaceutical Industries Inc.	4	$71
Jazz Pharmaceuticals Inc.	2	$65
Agios Pharmaceuticals, Inc.	3	$63
Stemline Therapeutics Inc.	2	$59
Tersera Therapeutics LLC	2	$55
Pharmaessentia USA Corporation	2	$51
Amneal Pharmaceuticals LLC	2	$50
Servier Pharmaceuticals LLC	2	$48
Sumitomo Pharma America, Inc.	2	$48
Beone Medicines USA, Inc.	2	$47
Beigene USA, Inc.	2	$46
Iovance Biotherapeutics, Inc.	2	$46
Progenics Pharmaceuticals, Inc.	2	$46
Bayer	2	$45
Pharmacosmos Therapeutics Inc.	2	$40
Deciphera Pharmaceuticals Inc.	1	$38
Recordati_rare_diseases_inc.	2	$37
ADC Therapeutics America, Inc.	2	$33
Regeneron Healthcare Solutions, Inc.	1	$33
Azurity Pharmaceuticals, Inc.	2	$31
Aimmune Therapeutics, Inc.	1	$30
Geron Corporation	1	$30
Fresenius Kabi USA, LLC	1	$27
Napo Pharmaceuticals Inc	1	$26
Corcept Therapeutics	1	$25
Exelixis Inc.	1	$24
Springworks Therapeutics, Inc.	1	$21
Rigel Pharmaceuticals, Inc.	1	$20
Accord Healthcare, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$107

How this compares

$10,044 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RevlimidLenalidomide	26	$474,373
Famciclovir	18	$1,614
Prochlorperazine Maleate	50	$1,341
Ondansetron OdtOndansetron	51	$675
Acyclovir	30	$521
Dexamethasone	25	$436
Lorazepam	42	$344
Lidocaine-PrilocaineLidocaine/Prilocaine	25	$333
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	19	$195
Letrozole	14	$141
Levofloxacin	12	$114
Gabapentin	11	$109
Zolpidem Tartrate	11	$96
Prednisone	17	$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Bristol Myers SquibbRevlimid	$137	$474,37326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Walnut Creek

Rhonda HewittStanford$917K
Linda TrinhIrvine$899K
Denise SinagaNorthridge$728K
Debbie TaySanta Monica$642K
Joe GorelickCampbell$638K
Lynsey LakinArcadia$540K
Kelly ChoiRancho Cucamonga$483K
Hamta ZareStanford$428K
Shawna ChrismanRoseville$425K
Angelina CollinsSan Diego$356K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →